Slide 1: ORIC-944 Dose Exploration Data Update
ORIC-944 Dose Exploration Data Update November 13, 2025 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us”
Slide 3: ORIC-944 Advanced into Combination Development with AR Inhibitors
ORIC-944 Advanced into Combination Development with AR Inhibitors Key Eligibility Patients with mCRPC Previously treated with an ARPI (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide) May have received up to 1 line of chemotherapy Phase 1b, Multicenter, Open-Label Trial (in Collaborati
Slide 4: Phase 1b Combination Dose Exploration in Previously Treated Patients with mCRPC
ORIC-944 Phase 1b Combination Dose Exploration in Previously Treated Patients with mCRPC Patients previously treated with a median of three prior therapies, including abiraterone and a variety of other approved and investigational treatment regimens Demographics and Baseline Characteristics Characte
Slide 5: Continues to Demonstrate Strong Clinical Activity with Apalutamide and with Darolutamide in Post-Abiraterone mCRPC
ORIC-944 Continues to Demonstrate Strong Clinical Activity with Apalutamide and with Darolutamide in Post-Abiraterone mCRPC Patients PSA Response Data of ORIC-944 Plus Apalutamide or Darolutamide (N=20) Response Unconfirmed Confirmed PSA50 11/20 (55%) 8/20 (40%) (1) PSA90 4/20 (20%) 4/20 (20%) 400 m
Slide 6: ctDNA Analysis Reveals Impressive Molecular Response for ORIC-944 Plus in Post-Abiraterone mCRPC Patients
ctDNA Analysis Reveals Impressive Molecular Response for ORIC-944 Plus Apalutamide or Darolutamide in Post-Abiraterone mCRPC Patients ctDNA Response Data of ORIC-944 Plus Apalutamide or Darolutamide (n=17) (1) Note:Data as of September 22, 2025. Waterfall plot displays patients previously treated wi
Slide 7: ctDNA Clearance with ORIC-944 Plus Is Superior to Standard of Care Therapies
ctDNA Clearance with ORIC-944 Plus Apalutamide or Darolutamide Is Superior to Standard of Care Therapies Trial IMbassador250 FIRSTANA / PROSELICA ORIC Phase 1b Treatment Enzalutamide Docetaxel or cabazitaxel ORIC-944 + AR inhibitor Size n=171 n=135 n=17 % Patients with Detectable ctDNA at Entry 80%
Slide 8: ORIC-944 in Combination with Apalutamide and with Darolutamide Has Been Generally Well Tolerated to Date
ORIC-944 in Combination with Apalutamide and with Darolutamide Has Been Generally Well Tolerated to Date Dose Level (QD) 400 mg (n=3) 600 mg (n=9) 800 mg (n=5) 1200 mg (n=3) Total (N=20) Preferred Term, n (%) Grade 1-2 Grade 3 Grade 1-2 Grade 3 Grade 1-2 Grade 3 Grade 1-2 Grade 3 Grade 1-2 Grade 3 D
Slide 9: Combination of ORIC-944 + AR Inhibitors Compares Favorably to Competitor PRC2 Inhibitor + AR Inhibitor and to AR Inhibitor Monotherapy
Combination of ORIC-944 + AR Inhibitors Compares Favorably to Competitor PRC2 Inhibitor + AR Inhibitor and to AR Inhibitor Monotherapy ORIC-944 Phase 1b Update (November 2025) PSA50 PSA90 SAFETY (All Gr / Gr ≥3) ORIC-944 + Apalutamide or Darolutamide Mevrometostat + Enzalutamide Enzalutamide Diarrhe